New flavonoid with antidiabetic and antioxidant potential from *Tetrastigma angustifolia* (Roxb.) Deb leaves

Julfikar Ali Junejo*, Kamaruz Zaman1, Mohammed Ali2, Mithun Rudrapal1

1Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam, India, 2Department of Pharmacognosy and Phytochemistry, Faculty of Pharmacy, Jamia Hamdard, Hamdard Nagar, New Delhi, India

Ethnomedicinal survey documents the traditional practices of *Tetrastigma angustifolia* leaves in the management of diabetes in the North-eastern region of India. The present study was aimed at isolation of possible antidiabetic principle(s) from *T. angustifolia* leaves and evaluation of antidiabetic efficacy of isolated compound(s) in experimental animal model. The methanolic extract of *T. angustifolia* leaves was obtained by Soxhlet extraction method and subjected to silica gel column chromatography (100-200 mesh). Fraction 18-176 chloroform:methanol (70:30) yielded a pale yellow colored compound. The structure of pure compound was elucidated with the help of UV, IR, NMR and Mass spectrometric/techniques. The antioxidant activity of the isolated compound was evaluated in vitro by various radical scavenging assay methods. Oral acute toxicity study was carried out according to OECD guideline 423 in Wistar rats. The antidiabetic efficacy of the isolated compound was evaluated in STZ-induced diabetic rats at the dose of 5 mg/kg b.w. for duration of 21 days. The present study reports a new flavonoid compound isolated from the methanolic extract of *T. angustifolia* leaves and identified as 8-hydroxyapigenin 7-O-D-glucopyranoside. The flavonoid compound exhibited potent antidiabetic (hypoglicemic) activity in STZ-induced diabetic rats with promising antioxidant (radical scavenging activity) potential in vitro.

**Keywords:** *T. angustifolia*. Leaves. Flavonoid. Antidiabetic. Antioxidant. Lead molecule.

INTRODUCTION

Diabetes mellitus (or Diabetes) is a metabolic disorder characterized by hyperglycemia with abnormal carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action or both (Amira et al., 2016). Hyperglycemia is usually accompanied by polyuria, polydipsia, weight loss, sometimes polyphagia, blurred vision and also susceptibility to infectious illness. In diabetes, chronic hyperglycemic condition may lead to several health complications such as cardiovascular (cardiomyopathy), neurological (neuropathy), renal (nephropathy) and ocular (retinopathy) complications (Shokeen et al., 2008). The prevalence of diabetes is increasing with the global rise of obesity and related lifestyle disorders like heart diseases and hyperlipidaemia. According to the latest report of World Health Organization (WHO, 2016), approximately 420 million adults are living with diabetes mellitus. Type 2 diabetes mellitus (Non-insulin Dependent Diabetes Mellitus) is alone responsible for up to 90% of total diabetes prevalence, which is the fourth leading cause of death worldwide (Irudayaraj et al., 2012; Kumar, Kumar, Om, 2011).

Oxidative stress (OS) is believed to be the underlying cause of cellular injury, tissue damage or organ dysfunctions commonly associated with diabetic complications. OS refers to elevated intracellular levels of reactive oxygen species (ROS) that cause damage to bio-molecules like lipids, proteins and DNA (Mahdi et al., 2009).
In view of above facts, the present study was aimed at isolation of antidiabetic principle(s) from the *T. angustifolia* leaves, along with evaluation of antidiabetic potential of isolated compounds(s) in STZ-induced diabetic rats. Accordingly, a new flavonoid was isolated from the methanolic leaf extract of *T. angustifolia*, and the toxicological, antidiabetetic and antioxidant properties of the isolated flavonoid were studied using standard *in vitro* and *in vivo* experimental models. Since a biochemical relationship exists between hyperglycemia and cellular oxidative stress in diabetes, the evaluation of antioxidant property was also carried out along with the antidiabetic activity to assess the antidiabetic potential of isolated flavonoid as novel herbal antioxidant.

**MATERIAL AND METHODS**

**Chemicals and analysis**

All chemicals, solvents and reagents used in the study were of analytical grade and were procured from Rankem, Mumbai and Himedia Laboratories Ltd., Mumbai. Streptozotocin (STZ) was procured from Sigma-Aldrich, Germany. Commercial reagent kits used for determination of biochemical parameters and enzymatic assays were purchased from SPAN Diagnostics Ltd., Surat (India). Melting points (MP) were measured in open capillaries on an electrically heated melting point apparatus. Thin layer chromatography (TLC) (0.5 mm thick layer) was carried out on silica gel G plates with fluorescent indicator (Merck, Germany) and spots were visualized by iodine vapors. Ultraviolet (UV)-visible spectra were recorded on Shimadzu UV-1700 UV-visible spectrophotometer. Infrared (IR) spectra were obtained on a Bruker AlphaFourier Transform (FT-IR) spectrometer using KBR disc. 'H & 'C Nuclear Magnetic Resonance (NMR) spectra were recorded on Bruker Avance II 400 FT-NMR spectrometer at 400 and 100 MHz, respectively using tetramethylsilane (TMS) as an internal standard (δ 0.00 ppm) and deuterated dimethyl sulfoxide (DMSO-d₆) as a solvent. Mass spectra were obtained on a LC–MS Water 4000 ZQ instrument using electrospray ionization (ES⁺).

**Plant material**

Fresh leaves of *Tetrastigma angustifolia* (Roxb.) Deb was collected from forest areas of Dibrugarh district, Assam (India) during the month of December.
2014. The plant species was identified and authenticated by Dr A. A. Mao, Scientist E, Botanical Survey of India, Eastern Regional Centre, Shillong (India). A voucher specimen (BSI/ERC/Tech./Plant Iden./2014/830) of the identified plant species was deposited in the Herbarium of the Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh.

**Extraction and isolation of the active compound**

The plant material (1.5 kg leaves) was air-dried under shade, coarsely powdered (Sieve no. 40) and defatted with petroleum ether (60-80 °C) using Soxhlet apparatus by successive solvent extraction method (Chakraborty, Saha, Mukhapadhyay, 2009). Later, extraction was performed using methanol using Soxhlet apparatus and the extracted sample was evaporated to dryness using rotary vacuum evaporator. The final yield of the extract was 24.32%, calculated per dry weight of powdered leaves. The dried methanolic extract (200 g) obtained as black brown residue was then subjected to column chromatography (silica gel packed column, 100-200 mesh, 250 g) by pre-adsorbing with silica gel (150 g). The extract was eluted first using chloroform (100%), followed by the mixture of chloroform and methanol at various ratios (90:10, 70:30, 50:50, 30:70 & 10:90) and then finally by methanol (100%). Fractions (200 mL each) obtained from the column were collected and combined on monitoring TLC. Thin layer Chromatography studies were performed using ready made pre-coated silica gel plates (Merck) with fluorescent indicator. Two hundred fractions were obtained. Fraction 18-176, chloroform:methanol (70:30) yielded a pale yellow colored compound. The crude compound was recrystallized from methanol. The compound was identified as flavonoid (TAY) with the chemical name of 8-hydroxy-apigenin-7-O-β-D-glucopyranoside. The presence of flavonoids in the extract was determined using Pews’ test (Anwal et al., 2014). 1.0 mL of aqueous extract (5%w/v) was mixed with 0.02 g of metallic zinc and 1.5 mL conc. sulphuric acid. The formation of red color indicated the presence of flavonoids.

**Test animals**

Healthy Wistar male albino rats (240-260 g) were maintained under standard environmental conditions (temperature 25± 2 °C, relative humidity 50±5%) with a 12 h light/dark cycle. They were fed on with normal laboratory chow pellet diet and drinking water was given ad libitum. Animals were allowed to acclimatize for 7 days before commencement of the experiment. The animals were used with the approval of the Institutional Animal Ethics Committee (Approval no. IAEC/DU/50 dt. 24.9.13) under guidelines set by the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), New Delhi (India).

**In vitro antioxidant activity**

The in vitro antioxidant activity of the isolated flavonoid, TAY was carried out using the following three assay methods in accordance with previously reported procedures with minor modifications.

**Superoxide radical scavenging activity**

Superoxide radical scavenging activity was determined by the nitro blue tetrazolium (NBT) reduction method (McCord, Fridovich, 1969). In this assay, the non-enzymatic phenazinemethosulfate/nicotinamide adenine dinucleotide (PMS/NADH) system generates superoxide radicals, which reduce NBT to a purple color formazan. The reaction mixture contained phosphate buffer (0.5 mL, 100 mM, pH 7.4), 1.0 mL of NADH (0.4 mM), 1.0 mL of NBT (0.156 mM), 0.1 mL of PMS (0.06 mM) and 3 mL of the TAY STANDARD drugs (quercetin & gallic acid) of various concentrations (10-50 µg/mL, in 90% ethanol). After incubation at 25 °C for 1 h, the absorbance of the reaction mixture was measured at 560 nm against an appropriate blank to determine the quantity of formazan formed.

**Hydroxyl radical scavenging activity**

Hydroxyl radicals were generated by the Fenton reaction using Fe³+/ascorbate/EDTA/H₂O₂ system. The hydroxyl radical generated in the system attacks deoxyribose which eventually results in the formation of thiobarbituric acid (TBA), which reacting substance (TBARS) which was estimated (Elizabeth, Rao, 1990). The reaction mixture contained 0.1 mL of 2-deoxy-2-ribose (10 mM), 0.33 mL of phosphate buffer (50 mM, pH 7.4), 0.1 mL of FeCl₃ (0.1 mM), 0.1 mL of methylenediamine tetra-acetic acid (EDTA) (0.1 mM), 0.1 mL of H₂O₂ (2 mM), 0.1 mL of ascorbic acid (1 mM) and 1.0 mL of the reaction mixture was incubated at 37 °C for 2 h, and the absorbance of the reaction mixture was measured at 532 nm against an appropriate blank to determine the quantity of formazan formed.
of various concentrations (5-50 µg/mL) of the TAY/standards (quercetin & gallic acid). After incubation for 45 min at 37 ºC, 1.0 mL of 2.8% (v/v) TCA, and 1.0 mL of [thiobarbituric acid, TBA, 0.5% (v/v) in 0.025 mol/L NaOH solution containing 0.2% (w/v) of butylated hydroxyl anisole, BHA] were added in the reaction mixture, and the mixture was incubated at 95 ºC for 15 min to develop the pink chromogen. After cooling, the absorbance was measured at 532 nm against an appropriate blank solution.

**Lipid peroxidation scavenging activity**

The Fe³⁺/ascorbic acid-dependent non-enzymatic lipid peroxidation in the liver extract was performed as follows. Reaction mixture (0.5 mL) containing rat liver homogenate (0.1 mL, 25% w/v) in Tris-HCl buffer (40 mM, pH 7.0), KCl (30 mM), FeCl₃ (0.16 mM) and ascorbic acid (0.06 mM) was incubated for 1 h at 37 ºC in the presence and absence of the TAY/standard drugs (quercetin & gallic acid) at various concentrations (50-250 µg/mL). The lipid peroxide formed was measured by TBARS formation (Ohkawa, Ohishi, Yagi, 1979). For this incubation mixture 0.4 mL was treated with sodium dodecyl sulphate (8.1%, 0.2 mL), TBA (0.8%, 1.5 mL) and acetic acid (20%, 1.5 mL, pH 3.5). The total volume was then made up to 4.0 mL by adding distilled water and kept in a water bath at 100 ºC for 1 h. After cooling, 1 mL of distilled water and 5.0 mL of a mixture of n-butanol and pyridine (10:1 v/v) were added to the reaction mixture, shaken vigorously and centrifuged at 4000 rpm for 10 min. The butanol-pyridine layer was removed and its absorbance at 532 nm was measured to quantify TBARS.

In all the three above methods, the percent inhibition of scavenging activity was calculated using the following equation (Eq. 1).

\[
\text{Percent inhibition} \, (\%) = \frac{A_{\text{control}} - A_{\text{test}}}{A_{\text{control}}} \times 100
\]  

where, \(A_{\text{control}}\) is the absorbance of the control and \(A_{\text{test}}\) represents the absorbance of a test substance (TAY/standard drug).

Tests were performed in triplicate and values were obtained as mean ± SEM of three independent studies. Results were evaluated by comparing the percent inhibition of activity of the TAY with that of standard drugs. Quercetin and gallic acid were used as standard drugs.

**Acute oral toxicity study**

Over-night fasted rats were randomly divided into six groups of six animals each. Rats of two different groups were administered with a single dose of 2000 mg/kg b.w. of TAY. Normal control was given vehicle alone. The animals were observed individually for first one hour for any gross behavioral changes like drowsiness, restlessness, writhing, convulsions and symptoms of toxicity and mortality, if any, and then periodically for the next 24 h, and then at every 24 h for any signs of acute toxicity over a period of 14 days. The acute toxicity study was done as per OECD guideline 423 (Oliveira et al., 2008).

**Oral Glucose tolerance (OGT) test**

This test was performed in overnight fasted normal rats according to the method reported by Junejo et al. (2014). Animals were divided into four groups of six each. Group I rats (normal control) were treated with vehicle alone. Group II was treated with TAY at 5 mg/kg b.w. dose. Group III rats were treated with metformin hydrochloride (5 mg/kg b.w.). Carboxymethylcellulose (CMC) solution (0.5% w/v in normal saline) was used as vehicle. Glucose 2 g/kg was fed orally for 30 min after the administration of TAY or metformin hydrochloride. Blood was withdrawn from the tail vein at 0, 30, 60, 90, and 120 min, and glucose levels in blood were estimated by the GOD-POD method (Ye, Shen, Xie, 2002).

**Hypoglycemic activity in streptozotocin-induced diabetic rats**

Type II diabetes was induced in overnight fasted animals by a single intraperitoneal (i.p) injection of streptozotocin (STZ, 55 mg/kg b.w. in normal saline) (Amira et al., 2016; Shokeen et al., 2008). The animals confirmed as diabetic (after 72 h of STZ injection) by the elevated plasma glucose levels (200-300 mg/dL) was used for the experiment. The animals were divided randomly into five groups of six rats in each group. Group I rats served as normal control and were given vehicle (0.5% CMC w/v in normal saline) alone. Group II rats served as diabetic control and were administered with vehicle alone. Group III was treated with TAY at 5 mg/kg b.w. Group IV rats were received the standard drug, metformin hydrochloride (5 mg/kg b.w.). Treatments were given orally using a canulaonce daily for a period
of 21 days. Blood was collected from the tail vein each time for the determination of glucose levels on 0, 7, 14 and 21 day. Blood glucose levels were measured by the GOD-POD method.

Liver and kidney function tests

The initial and final body weights were measured. Liver tissues were excised, blotted, weighed and stored at -70 °C for assay of glycogen content. Liver glycogen was estimated by the method of Carroll and co-workers (Carroll, Longley, Roe, 1956). Blood was collected by cardiac puncture in dry test tubes containing a mixture of potassium oxalate and sodium fluoride (1:3) and allowed to coagulate in ambient temperature for 30 min. The serum was separated by centrifugation (2000 rpm, 10 min) for estimation of various biochemical parameters. Serum insulin levels were measured by the microplate ELISA method using a commercial kit (SPAN Diagnostics Ltd.). Serum lipid profile was estimated using commercially available kits (SPAN Diagnostics kit). Triglycerides (TG) and Total cholesterol (TC) were estimated by enzymatic methods (Trinder, 1969; Lopes et al., 1977), HDL (High density lipoprotein) cholesterol by phosphotungstic acid method (Lopes et al., 1977; Allain et al., 1974) and LDL (low density lipoprotein) cholesterol were calculated by Friedewald’s formula (Friedewald, Levy, Frederickson, 1972).

Serum was used to estimate glutamate oxaloacetate transaminase (GOT), glutamate pyruvate transaminase (GPT) and alkaline phosphatase (ALP), total protein (TPR) and creatinine (CRTN). SGOT and SGPT were measured by UV kinetic method (Bergmeyer et al., 1976) and ALKP was estimated by PNPP method (Klin, 1972; Seligman et al., 1950). TPR was measured by Bradford Macro method (Bradford, 1976), while CRTN was by picrate method (Henry, Canon, Winkelman, 1974).

**In vivo antioxidant activity**

On 21st day, all the groups of animals were anaesthetized using diethyl ether; liver, was dissected out, washed with normal saline and one part was preserved in 10% formalin for histopathological studies. The other part of liver was homogenized by ice chilled Tris-HCl buffer and used for activities/levels of superoxide dismutase (SOD) (Minami, Yoshikawa, 1979), catalase (Xu, Yuan, Lang, 1997), reduced glutathione (GSH) (Beutler, Duron, Kelly, 1983), glutathione peroxidase (GPx) (Rotruck et al., 1973), and malondialdehyde (MDA) (Mesbah et al., 2004). The malondialdehyde (MDA) production is a direct indicator of lipid peroxidation (LPO) process that was measured by TBA reaction using an ELISA reader (at 532 nm).

**Histopathological studies**

At the end of 21st day of treatment, the animals were fasted for 12 h, anaesthetized using diethyl ether and sacrificed by cervical dislocation. Pancreas was instantly dissected out, excised and rinsed in ice-cold saline solution. Tissues were processed as follows. A portion of pancreas tissue was fixed in 10% formalin fixative solution for 4 days. After fixation, tissues were dehydrated in ethanol (70-95%), cleared in xylene, and embedded in paraffin, solid transverse sections of 4-5 µm thickness were obtained by using a rotary microtome. The section were stained with haematoxylin-eosin and histopathological observations were carried out under a light microscope (40x) (Irudayaraj et al., 2012; Kumar, Kumar, Om, 2011).

**Statistical analysis**

Statistical analysis was carried out using GraphPad Prism 5.0 (San Diego, USA) (IBM SPSS 19.0 statistical software package, for Windows). Results were calculated as mean±SEM of triplicate studies. Data were analyzed by one-way ANOVA followed by Student’s t-test (Sabu, Smitha, Kuttan, 2002). For biochemical estimations, statistical significance differences were observed with respect to negative control (p<0.01, p<0.05).

**RESULTS**

Identification of isolated compound

The structure of the isolated flavonoid, **TAY** represented in Figure 1 was elucidated by UV, IR, 1H NMR, 13C NMR and Mass spectroscopic/spectrometric analyses.

**TAY** (Fraction 18-176): UV: λ<sub>max</sub> (MeOH): 272, 304, 340 nm (log ε 5.6, 1.1, 0.9); IR<sub>νmax</sub> (KBr): 3465, 3372, 3315, 3241, 2948, 2833, 1685, 1648, 1562, 1422, 1221, 1093, 876 cm<sup>-1</sup>; 1H NMR (DMSO-d<sub>6</sub>): δ 8.02 (1H, d, J=8.1 Hz, H-2), 7.95 (1H, d, J= 8.4 Hz, H-6), 6.94 (1H, d, J= 8.1 Hz, H-5), 6.28 (1H, s, H-6), 6.28 (1H, s, H-3), 6.71 (1H, s, H-6), 6.28 (1H, s, H-3), 5.01 (1H, d, J=7.1 Hz,
H-1'), 4.68 (1H, m, H-5'), 4.50 (1H, m, H-2'), 3.81 (1H, m, H-3'), 3.54 (1H, m, H-4'), 3.18 (2H, d, J=4.8 Hz, H-6'); 13C NMR (DMSO-d6): δ 163.00 (C-2), 102.92 (C-3), 182.55 (C-4), 161.59 (C-5), 98.61 (C-6), 164.43 (C-7), 156.24 (C-8), 160.86 (C-4), 114.27 (C-5), 104.51 (C-10), 122.08 (C-1), 128.93 (C-2), 116.28 (C-3), 160.86 (C-4), 114.79 (C-5), 129.41 (C-6), 105.07 (C-1'), 79.15 (C-2), 73.85 (C-3), 71.05 (C-4), 82.28 (C-5), 61.78 (C-6); ES+MS m/z (rel. int.): 448 [M]+ (C21H20O11) (59.0), 431 (66.3), 330 (1.2), 302 (61.9), 285 (9.1).

The isolated flavonoid (TAY) was obtained as pale yellow amorphous powder (480 mg) with a melting range of 250-251 °C. The molecular ion (M+) peak was obtained at m/z 448.0 with a relative intensity of 59.0 which corroborates the molecular formula of the compound as C21H20O11. The NMR spectral data also supported the structure of the compound. A signal at δ 6.711 (1H, s) showed the characteristic feature of a proton at 3-position of the flavone skeleton. The presence of chelated hydroxyl group was shown by absorption bands at 3372 and 1648 cm⁻¹ in the IR spectrum with a shoulder at λ 340 nm in the UV spectrum and by a sharp singlet at δ 13.179 of 1H NMR spectrum. Location of chelated hydroxyl group at 5-position was shown by a bathochromic shift at λ 430 nm with MeOH/AlCl₃ in UV. It was found to contain β-D-glucopyranosyl unit fused through O-glycosidic linkage with 7-position of ring A as evident from the six signals of 13C NMR spectrum at δ 105.079 (C-1'), 79.152 (C-2'), 73.851 (C-3'), 71.052 (C-4'), 82.289 (C-5'), 61.788 (C-6') and p-di-substituted phenyl nucleus at 2-position of ring B as disclosed by its signals of four aromatic protons in 1H NMR constituting AA'BB' systems (1H, d, J=8.1 Hz, H-2' at δ 8.036; 1H, d, J=8.4 Hz, H-6' Hz at δ 7.940; 1H, d, J=8.1 Hz, H-3' at δ 6.932 and 1H, d, J=8.4 Hz, H-5' at δ 6.905). Also, β-position of anomeric proton of D-glucopyranosyl unit at 1'-position was revealed by J value of 7.1 Hz of its characteristic signal at δ 5.006 in 1H NMR spectrum. Furthermore, p-di-substitutions of hydroxyl groups at 5- and 8-positions of aromatic ring A was confirmed by blue color as positive response diagnosed by Gibb's test (Gibbs, 1974). A thorough spectral interpretation of the spectra of the compound and chemical analysis suggested that the compound is 8-hydroxyapigenin 7-O-β-D-glucopyranoside. This compound is reported for the first time as a new compound from the species of T. angustifolia.

**FIGURE 1** - Structure of isolated flavonoid, TAY.

**In vitro antioxidant activity**

**Superoxide radical scavenging activity**

TAY showed superoxide radical scavenging activity in a concentration dependent manner. At the concentration of 50 µg/mL, TAY exhibited 93.34±0.43% of scavenging activity, while quercetin showed 93.85 ± 0.36% of scavenging activity at the same concentration. The percent inhibitory activity of TAY was found significant (p<0.05) as compared to the standard drug, quercetin (Figure 2).
New flavonoid with antidiabetic and antioxidant potential from *Tetrastigma angustifolia* (Roxb.) Deb leaves

**Figure 2** - Superoxide radical scavenging activity. Values are mean ± SEM of three replicate experiments. %Scavenging activity of *TAY* is statistically significant at *p*<0.05, compared to quercetin (standard).

**Figure 3** - Hydroxyl radical scavenging activity. Values are mean ± SEM of three replicate experiments. %Scavenging activity of *TAY* is statistically significant at *p*<0.05, compared to quercetin (standard).

**Figure 4** - Lipid peroxidation scavenging activity. Values are mean ± SEM of three replicate experiments. %Scavenging activity of *TAY* is statistically significant at *p*<0.05, compared to quercetin (standard).

**Figure 5** - OGT test. Values are mean ± SEM of three replicate experiments. Activities of *TAY* and metformin are statistically significant at *p*<0.05, compared to normal control.

**Hydroxyl radical scavenging activity**

The percent inhibition of hydroxyl radicals was 92.34±0.43% for *TAY* at the concentration of 50 µg/mL. The inhibitory activity of *TAY* was comparable with that of the standard drug, quercetin (94.85 ± 0.32%) at the same concentration. The percent scavenging activity of *TAY* was statistically significant (*p*<0.05) as compared to quercetin (Figure 3).

**Lipid peroxidation scavenging activity**

LP induced by Fe²⁺/ascorbate in rat liver homogenate was found to be inhibited by *TAY* in a concentration dependent manner and a considerable amount of lipid peroxidation inhibitory effect was observed by 89.19±0.22%, while, quercetin inhibited by 93.48±0.35%, at the concentration of 50 µg/mL (Figure 4). Test results were considered statistically significant (*p*<0.05) as compared to the standard drug, quercetin.

**Acute toxicity study**

No sign and symptoms of acute toxicity and mortality up to 2000 mg/kg body weight dose were observed during the whole experimental period. The body weight and food consumption were normal compared to vehicle treated rats. No significant changes in haematological and biochemical (serum lipids and liver enzymes) parameters were observed.

**Effect of *TAY* on OGT test in normal rats**

In OGT, *TAY* (5 mg/kg) showed significant (*p*<0.05) reduction of blood glucose load compared to normal control group (Figure 5). The activity of *TAY* is comparable to the standard drug, metformin (5 mg/kg).
Hypoglycemic activity of TAY in streptozotocin-induced diabetic rats

Effect of TAY on blood glucose levels in diabetic rats

There was abnormal increase in the levels of blood glucose in STZ-treated diabetic rats. After treatment with TAY (5 mg/kg) the blood glucose levels were markedly decreased in diabetic rats. The activity of TAY is statistically significant \((p<0.05)\) as compared to the normal control rats and is comparable to the standard drug, metformin (5 mg/kg). Results of the effect of TAY on blood glucose levels in normal and diabetic rats are summarized in Table I.

| TABLE I - Effect of TAY on blood glucose levels in normal and diabetic rats |
|---|---|---|---|---|
| **Group** | **Days** | **0 day** | **7th day** | **14th day** |
| | | | | **21st day** |
| Normal control | | 97.83 ± 2.10 | 101.92 ± 2.12 | 99.16 ± 3.23 | 103.92 ± 3.19 |
| Diabetic control | STZ (55 mg/kg, i.p) | 273.19 ± 1.92 | 282.29 ± 2.18 | 291.37 ± 3.91 | 332.99 ± 1.99 |
| Diabetic + TAY (5 mg/kg, p.o) | | 269.61 ± 3.44 | 286.33 ± 2.89 | 143.19 ± 3.19 | 121.30 ± 2.87 |
| Diabetic + Metformin (5 mg/kg, p.o) | | 276.54 ± 3.71 | 283.75 ± 2.83 | 118.82 ± 3.11 | 99.51 ± 2.43 |

Values indicate mean ± SEM \((n = 6)\)

Effect of TAY on body weight, plasma insulin and liver glycogen in diabetic rats

Table II depicts the effect of TAY on body weight, levels of plasma insulin and liver glycogen in normal and diabetic rats. In diabetic rats, the body weight, insulin level and glycogen content were significantly reduced. After 21 days of treatment with TAY (5 mg/kg), body weight, insulin level and glycogen content were significantly increased as compared to diabetic rats. Results are of TAY statistically significant \((p<0.05)\) as compared to the normal rats. The activity of TAY is comparable to the standard drug, metformin (5 mg/kg).

| TABLE II - Effect of TAY on body weight, plasma insulin and liver glycogen in normal and diabetic rats |
|---|---|---|
| **Group** | **Body weight in g** | **Plasma insulin (µU/mL)** | **Liver glycogen (mg/g tissue)** |
| | **0 day** | **21st day** | **0 day** | **21st day** |
| Normal control | 209.23 ± 3.30 | 226.21 ± 3.63 | 16.01 ± 2.21 | 73.54 ± 3.44 |
| Diabetic control | STZ (55 mg/kg, i.p) | 217.19 ± 2.44 | 183.44 ± 4.74 | 5.98 ± 5.38 | 31.89 ± 3.73 |
| Diabetic + TAY (5 mg/kg, p.o) | | 212.86 ± 2.86 | 219.45 ± 3.54 | 14.17 ± 4.11 | 70.63 ± 5.32 |
| Diabetic + Metformin (5 mg/kg, p.o) | | 218.18 ± 4.80 | 225.68 ± 3.10 | 15.95 ± 5.88 | 72.97 ± 5.83 |

Values indicate mean ± SEM \((n = 6)\)

\(^{p}<0.05, {^{\prime}p}<0.01\), compared with normal control values.

Effect of TAY on lipid profile in diabetic rats

The effect of TAY on serum lipid profile of diabetic rats is displayed in Table III. In diabetic rats, the levels
of triglycerides (TG), total cholesterol (TC), and low density lipoprotein (LDL) were increased and the level of high density lipoprotein (HDL) was decreased. In TAY (5 mg/kg) treated groups, the TG, TC and LDL levels were significantly reduced and the HDL level was significantly increased as compared to diabetic control rats. The activity of TAY is statistically significant \((p<0.05)\) as compared to the normal rats and is comparable to the standard drug, metformin (5 mg/kg).

**TABLE III - Effect of TAY on lipid profile in normal and diabetic rats**

<table>
<thead>
<tr>
<th>Groups</th>
<th>TG (mg/dL)</th>
<th>TC (mg/dL)</th>
<th>HDL (mg/dL)</th>
<th>LDL (mg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal control</td>
<td>91.20 ± 3.99</td>
<td>157.29 ± 3.11</td>
<td>42.13 ± 2.34</td>
<td>98.23 ± 3.24</td>
</tr>
<tr>
<td>Diabetic control STZ (55 mg/kg, i.p)</td>
<td>213.73 ± 2.58</td>
<td>279.57 ± 1.79</td>
<td>28.58 ± 3.13</td>
<td>203.75 ± 2.41</td>
</tr>
<tr>
<td>Diabetic + TAY (5 mg/kg, p.o)</td>
<td>132.62 ± 2.38*</td>
<td>161.50 ± 1.79*</td>
<td>45.89 ± 2.49</td>
<td>122.53 ± 3.17</td>
</tr>
<tr>
<td>Diabetic + Metformin (5 mg/kg, p.o)</td>
<td>117.96 ± 1.94</td>
<td>155.49 ± 2.53</td>
<td>49.85 ± 2.75</td>
<td>89.72 ± 2.83</td>
</tr>
</tbody>
</table>

Values indicate mean ± SEM \((n = 6)\)

*p<0.05, compared with normal control values.

**Effect of TAY on SGOT, SGPT, ALKP, TPR and CRTN in diabetic rats**

There was an abnormal increase in activities of SGOT, SGPT and ALKP in diabetic rats. After treatment with TAY (5 mg/kg), the activities of SGOT, SGPT and ALKP activities were significantly reduced in diabetic rats. A significant decrease in serum total protein (TPR) level and a significant increase in creatinine (CRTN) level were also observed in diabetic rats. After treatment with TAY at 5 mg/kg doses for 21 days the TPR level was significantly increased and CRTN level was significantly decreased compared to diabetic control rats. The effect of HAE on liver enzymes (SGOT, SGPT, ALKP) and TPR and CRTN is significant \((p<0.05)\) as compared to normal control animals and is similar to that of the standard drug, metformin (5 mg/kg).

**TABLE IV - Effect of TAY on SGOT, SGPT, ALKP, TPR and CRTN in normal and diabetic rats**

<table>
<thead>
<tr>
<th>Group</th>
<th>SGOT (U/L)</th>
<th>SGPT (U/L)</th>
<th>ALKP (U/L)</th>
<th>TPR (mg/dL)</th>
<th>CRTN (mg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal control</td>
<td>53.32 ± 2.72</td>
<td>44.81 ± 1.53</td>
<td>111.32 ± 3.75</td>
<td>9.11 ± 0.53</td>
<td>0.513 ± 0.031</td>
</tr>
<tr>
<td>Diabetic control STZ (55 mg/kg, i.p)</td>
<td>106.38 ± 1.95</td>
<td>90.84 ± 3.17</td>
<td>304.33 ± 2.63</td>
<td>4.79 ± 0.86</td>
<td>0.927 ± 0.028</td>
</tr>
<tr>
<td>Diabetic + TAY (5 mg/kg, p.o)</td>
<td>71.29 ± 3.11*</td>
<td>69.36 ± 3.64*</td>
<td>141.73 ± 3.17</td>
<td>8.15 ± 0.57</td>
<td>0.617 ± 0.056*</td>
</tr>
<tr>
<td>Diabetic + Metformin (5 mg/kg, p.o)</td>
<td>61.43 ± 1.89*</td>
<td>51.27 ± 2.76</td>
<td>128.82 ± 3.51**</td>
<td>8.92 ± 1.46*</td>
<td>0.567 ± 0.032**</td>
</tr>
</tbody>
</table>

Values indicate mean ± SEM \((n = 6)\)

*p<0.05, **p<0.01, compared with normal control values.

**Effect of TAY on liver enzymes and MDA**

Table V displays the activities of SOD, CAT, GSH and GPx in normal and diabetic rats. In STZ-treated diabetic rats, the activities of SOD, CAT, GSH and GPx were abnormally increased. TAY significantly \((p<0.05)\) reduced the activities of these antioxidant enzymes in diabetic rats as compared to normal rats. Increased levels of MDA, an indicator of LPO, in diabetic rats were significantly reduced after treatment with TAY (5 mg/kg) as compared to normal rats. The effect of TAY on liver enzymes and MDA are comparable with that of standard drug metformin (5 mg/kg).
TABLE V - Effect of TAY on SOD, CAT, GSH, GPx and MDA in normal and diabetic rats

<table>
<thead>
<tr>
<th>Treatment</th>
<th>SOD (U/mg protein)</th>
<th>CAT (U/mg protein)</th>
<th>GSH (U/mg protein)</th>
<th>GPx (U/mg protein)</th>
<th>MDA (LPO) (U/mg protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal control</td>
<td>9.05 ± 0.04</td>
<td>74.75 ± 3.45</td>
<td>18.11 ± 0.59</td>
<td>25.36 ± 2.57</td>
<td>0.64 ± 0.23</td>
</tr>
<tr>
<td>Diabetic control STZ (55 mg/kg, i.p)</td>
<td>5.68 ± 0.06</td>
<td>43.86 ± 2.52</td>
<td>7.89 ± 0.34</td>
<td>10.85 ± 0.79</td>
<td>0.94 ± 0.05</td>
</tr>
<tr>
<td>Diabetic + TAY (5 mg/kg, p.o)</td>
<td>8.64 ± 0.07*</td>
<td>70.54 ± 3.23*</td>
<td>16.14 ± 0.48</td>
<td>22.94 ± 0.68</td>
<td>0.723 ± 0.57</td>
</tr>
<tr>
<td>Diabetic + Metformin (5 mg/kg, p.o)</td>
<td>8.95 ± 0.08</td>
<td>73.85 ± 4.39</td>
<td>18.02 ± 1.20*</td>
<td>24.83 ± 0.68</td>
<td>0.69 ± 0.13</td>
</tr>
</tbody>
</table>

Values indicate mean ± SEM (n = 6)
*p<0.05, compared with normal control values.

**Histopathological observations**

Histopathological studies of pancreas of STZ-treated diabetic rats exhibited reduction in the dimensions of islets, damaged β-cell population and extensive necrotic changes followed by fibrosis and atrophy (B). TAY (5 mg/kg) and metformin treated rats restored the necrotic and fibrotic changes and also increased the number and increased the size of the islets (C). In normal control group normal acini and normal cellular in the islets of langerhans in the pancreas were observed (A). The changes in pancreas morphology in metformin treated group (D) are similar to TAY treated rats. The effect of TAY on pancreatic section in normal and diabetic rats is appended in Figure 6.

**DISCUSSION**

The flavonoid compound, TAY isolated from methanolic extract of T. angustifolia leaves exhibited no toxicities or any mortalities up to a dose of 2000 mg/kg b.w. in experimental rats. Results of acute toxicity study therefore indicates high margin of safety of the isolated flavonoid, TAY. OGT is used to determine the altered carbohydrate metabolism during post glucose administration (Ceriello, 2005). In OGT, TAY showed promising response in lowering increased glucose load of blood. The hypoglycemic effect of TAY was also found significant with marked decrease in fasting blood glucose levels in STZ-induced diabetic rats. Besides glucose lowering effect, TAY significantly increased the level of serum insulin. It is therefore suggested that the hypoglycemic response of TAY might be attributed mainly due to the stimulation of insulin secretion from β-cells of pancreas. Intraperitoneal administration of STZ destroys partially pancreatic β-cells and residual β-cells that secrete insufficient insulin, which ultimately results in diabetes mellitus (Type 2). Increased insulin levels in blood promotes peripheral glucose uptake into the muscle and adipose tissue or reduces the production of glucose by inhibiting hepatic glycogenolysis/gluconeogenesis (Shirwaikar,
New flavonoid with antidiabetic and antioxidant potential from *Tetrastigma angustifolia* (Roxb.) Deb leaves

Rajendran, Punitha, 2005; Irudayaraj *et al.*, 2012). The reversal of hyperglycemia is therefore observed due to increased insulin secretion from regenerated β-cells of pancreas (Punith, Manohara, 2006). Histopathological observations of our study also support the above fact. However, the possible mode(s) of antidiabetic action of *TAY* might be stimulation of insulin secretion from the β-cells of pancreas or reduction of insulin resistance by increased utilization of peripheral glucose.

The characteristic loss of body weight in STZ-induced diabetic rats was probably due to the increased muscle wasting and protein catabolism (Salahuddin, Jalalpure, 2010). Diabetic rats treated with *TAY* showed an improvement in body weight in diabetic rats. This signifies the protective effect of *TAY* indigradation of structural proteins. The ability of *TAY* to protect body weight loss might be due to improvement in insulin secretion and consequent hypoglycemic response. Glycogen synthesis in the liver and skeletal muscles of rats gets impaired in diabetes (Huang *et al.*, 2000). The liver glycogen content was markedly reduced in diabetic animals, which was in proportion to insulin deficiency. *TAY* increased significantly the liver glycogen content of diabetic rats, which could be due to increased insulin secretion. The decrease in hepatic glycogen content in diabetes is due to the lack of insulin which ultimately results in the inactivation of glycogen synthase enzyme (Whitten, Hems, 1975). It is therefore suggested that reactivation of the glycogen synthase enzyme primarily restores the level of liver glycogen.

Elevation of plasma lipid concentration in diabetes is well documented (Chase, Glasgow, 1976). The most common lipid abnormalities in diabetes are hypertriglyceridemia and hypercholesterolemia that are usually linked to obesity, atherosclerosis and other diabetic complications like coronary heart disease (Khan, Abraham, Leelamma, 1995). Hypertriglyceridemia is also associated with metabolic consequences of hypoinsulinemia, insulin resistance and insulin intolerance (Gingsberg, 1994). The increase in serum TG and TC observed in untreated diabetic rats is in agreement with the findings of Annie *et al.* (2004). Under normal circumstances insulin activates enzyme lipoprotein lipase and hydrolyses triglycerides. Insulin deficiency results in failure to activate the enzymes leading to hypertriglyceridemia (Pushparaj, Tan, Tan, 2000). The significant control of the levels of serum lipids in the *TAY* treated diabetic rats might be attributed to improvements in serum insulin levels (Annie *et al.*, 2004). Significant lowering of LDL cholesterol and raise in HDL cholesterol were observed in treated diabetic rats. (Luc, Fruchart, 1991).

An increase in the activities of SGOT, SGPT and ALP in diabetic rats occurs due to their leakage from liver cytosol into the blood stream which is an indicator of the toxic effect of STZ to liver cells (Kasetti *et al.*, 2010). Treating with *TAY* reduced the activity of these enzymes in liver in diabetic rats. It indicates the protective role of flavonoid compound over liver enzymes in diabetic state. Reduction in levels of plasma TPR and CRTN were also observed in diabetic rats. This is be due to the distinct metabolic renal dysfunction in diabetic state, leading to a negative nitrogen balance, enhanced proteolysis and decreased protein synthesis (Tuvemo *et al.*, 1997; Almdal, Vilstrup, 1988). After treatment *TAY*, significant improvement in protein levels was observed in diabetic rats. It indicates that the flavonoid compound prevented the progression of renal damage in diabetic rats.

SOD, CAT, GSH and GPx are enzymatic antioxidants that play a vital role in preventing oxidative damage to cells. SOD reduces the superoxide radical into hydrogen peroxide (H$_2$O$_2$). CAT catalyzes the reduction of H$_2$O$_2$ into oxygen and water molecule and thus protects the tissues against damaging effects of hydroxyl radicals. GSH and GPx are involved in the process (Eliza, Daisy, Ignacimuthu, 2010; Halliwell, Gutteridge, 1985). In diabetes mellitus, hyperglycemia causes inactivation of SOD, CAT, GSH and GPx by glycating these proteins which consequently induce cellular oxidative stress through lipid peroxidation (LPO) process. Malonaldehyde (MDA) is one of the end products in LPO process. LPO in the tissue homogenate was determined by measuring the amounts of MDA produced (Rosen *et al.*, 2001). Increased levels of SOD, CAT, GSH and GPx observed after treatment with *TAY* indicates the potential of flavonoid compound in the prevention of LPO and associated oxidative stress (OS) in diabetes. Decreased MDA level further supports the role of flavonoid compound in LPO process.

Increasing evidence in clinical studies suggest that OS plays a crucial role in the pathogenesis of both type 1 and type 2 diabetes mellitus. Diabetic complications (atherosclerosis, myocardial infarction, neuropathy, nephropathy) have long been associated with hyperglycemia and cellular OS (Irudayaraj *et al.*, 2012; Sabu, Smitha, Kuttan, 2002; Rosen *et al.*, 2001; John, 1991; Kayama *et al.*, 2015). Plant antioxidants play a vital
role in the alleviation of oxidative stress in diabetes. STZ produces oxygen radicals, which cause pancreatic injury and thus responsible for the increased blood glucose level in animals (Elizabeth, Rao, 1990; Halliwell, Gutteridge, 1985). Moreover, abnormally high levels of free radicals and simultaneous defects in natural antioxidant defense mechanisms (enzymatic) can lead to the development of insulin resistance. In our study, a marked decrease in the concentration of TBARS and MDA observed in *in vitro* and *in vivo* models, respectively, indicates decline in LPO of tissues and induced OS (Venkateswaran, Pari, 2003; Suresh, Menon, 1993). It signifies the potential role of the isolated flavonoid compound in lipid peroxidation mechanism as a powerful free radical scavenger or antioxidant. Superoxide directly initiates LPO and plays an important role in the formation of ROS like hydroxyl radicals, which in turn induce oxidative damage in lipids, proteins, and DNA. The direct effect of hydroxyl radicals in LPO is several folds more than the superoxide radical. The flavonoid could effectively scavenge these harmful radicals along with the inhibition of LPO by scavenging active oxygen species with the subsequent prevention of the propagation of free radical chain reactions. The reducing property of phenolic flavonoid indicates that it acts as electron donors, which reduce the oxidized intermediates involved in LPO process (Bajpai *et al.*, 2014). Studies (Hagerman *et al.*, 1998; Robak, Gryglewski, 1998) also suggest that high molecular weight plant flavonoids comprising hydroxylated aromatic ring systems serve as potent free radical scavengers due to the formation of reactive phenoxide radical. The phenoxide radical helps suppress LPO/OS through different chemical mechanisms, which includes free radical quenching, electron transfer, radical addition, or radical recombinations (Lamba *et al.*, 2000; Fang, Yang, Wu, 2002). It is now therefore assumed that the antioxidant property of isolated flavonoid compound is primarily responsible for its antidiabetic activity (Ramkumar *et al.*, 2009). The antioxidant action helps to reduce cellular OS and associated hyperglycemic conditions in diabetes (Kusirisin *et al.*, 2009; Bajpai *et al.*, 2014). The compound, 8-hydroxyapigenin 7-O-β-D-glucopyranoside is a glucoside of 8-hydroxy derivative of apigenin (4',5,7-trihydroxyflavone), a flavones occurring naturally as glycosides in many plant species. Apigenin and its 7-glucoside (Apigetrin), have several health benefits such as anticancer, neuroinflammation and antioxidant properties. Because of having potent hypoglycemic response in STZ-induced diabetic rats, the new flavonoid compound of herbal origin may be used as an antidiabetic drug in insulin-resistant diabetic (type 2) patients with potent antioxidant action.

**CONCLUSION**

The present study reports a new flavonoid compound, 8-hydroxyapigenin 7-O-β-D-glucopyranoside isolated from the methanolic extract of *T. angustifolia* leaves. The flavonoid compound possesses potent antidiabetic (hypoglycemic) activity with antioxidant (radical scavenging activity) potential in STZ-induced diabetic rats. The compound is reported for the first time as a novel flavonoid molecule from the species of *T. angustifolia*. Studies are in progress in our laboratory for further exploration of biochemical mechanism involved in the antidiabetic action of the isolated flavonoid. However, the isolated flavonoid may play a significant role in ameliorating diabetes mellitus with limited host toxicity or may be used as a lead molecule in the development of newer antidiabetic drug candidates for the treatment of insulin resistant diabetes mellitus.

**CONFLICT OF INTEREST**

We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

**ACKNOWLEDGEMENT**

The authors are thankful to Head, Dept. of Pharmaceutical Sciences, Dibrugarh University for his needful help and cooperation to carry out research work. The first author (JAJ) acknowledges the fellowship (SRF) support from the University Grants Commission (Grant number: F1-17.1/MANF-MUS-WES), New Delhi, India.

**REFERENCES**


New flavonoid with antidiabetic and antioxidant potential from Tetrastigma angustifolia (Roxb.) Deb leaves


Received for publication on 30th October 2018
Accepted for publication on 02nd January 2019